Drug
eluting balloons are angioplasty balloons that are
coated with an anti-proliferative drug, which is eluted in vessel
walls during the inflation of balloon, usually at nominal pressure
with a specific minimal inflation time. The active substance coated
on the drug eluting balloon should be lipophilic in nature to have a
high absorption rate through the vessel wall. Mostly paclitaxel is
used as active ingredient due to its high pharmacokinetic transfer
rate into the vessel wall and it is actively used in drug eluting
balloons in the U.S. market and has been already approved for use in
Europe.
Get
FREE In-Depth Sample Copy of Research @
https://www.coherentmarketinsights.com/insight/request-sample/2459
Market
Dynamics
Increasing
prevalence of coronary artery diseases is a major factor driving drug
eluting balloon market growth. According to American College of
Cardiology, June 2017, around 17.92 million cardiovascular deaths
were registered in 2015 worldwide. Moreover, key players in the
market are focused on adopting acquisition strategies in order to
gain access to innovative products and expand their product offerings
in the potential markets. For instance, in April 2010, Medtronic
acquired Invatec and affiliated companies. Invatec launched 4 new
drug eluting balloons in Europe in 2009 including In.Pact Amphirion,
In.Pact Admiral, In.Pact Pacific, and In.Pact Falcon. Medtronic is
focused on enhancing its international presence by expanding
treatment option for patients with cardiovascular disease.
Increasing
prevalence of coronary artery disease and diabetes is expected to
propel growth of the drug eluting balloon market
Drug
eluting balloon is an angioplasty balloon, which plays a vital role
in treatment of coronary artery disease. High prevalence of coronary
artery disease is expected to propel demand for angioplasty and other
treatments, which in turn is expected to drive the market growth.
According to the World Health Organization (WHO), around 3.8 million
men and 4.4 million women die, annually from coronary heart disease
worldwide. Moreover, the number of deaths from age 15 to 59 is around
1332 thousands and for above 60 years of age is around 5825
thousands.
Increasing
adoption of drug eluting balloon in North America is expected to
bolster the market growth
North
America holds dominant position in the global drug eluting balloon
market, owing to high prevalence of obesity, which further develops
cardiovascular and coronary artery diseases. In October 2017,
according to the National Center for Health Statistics (NCHS),
estimated the prevalence of obesity in adults was around 39.8% and in
youth 18.5% in the year 2015 -16 in the U.S. Increasing prevalence of
cardiovascular diseases developed from tobacco and smoking in the
region is also expected to boost the market growth.
Key
Players
Major
players operating in the global drug eluting balloon market include,
Medtronic, Becton, Dickinson and Company (BD), Boston Scientific
Corporation, Cook Medical, B. Braun Melsungen AG, Koninklijke Philips
N.V., Opto Circuits (India) Limited, Terumo Corporation, Surmodics,
Inc., and Biotronik.
Detailed
Segmentation:
Global
Drug Eluting Balloon Market, By Product Type:
-
Coronary Drug Eluting Balloon
-
Peripheral Drug Eluting Balloon
-
Others
Global
Drug Eluting Balloon Market, By End User:
-
Hospitals
-
CATH Laboratories
-
Ambulatory Surgical Centers
-
Others
Global
Drug Eluting Balloon Market, By Geography:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East
-
Africa
Request
For Customization of This Exclusive Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/2459
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
0 comments:
Post a Comment